# A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer

Source: https://onco.cc/trials/nct07739758/  
OnCo record `nct07739758` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing YL201 in small-cell lung cancer and non-small-cell lung cancer, now recruiting.

## Summary

A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer is a phase 3 interventional study registered as NCT07739758, led by MediLink Therapeutics (Suzhou) with Shanghai Henlius Biotech, and recruiting on the registry. Official title: A Phase III, Multicenter, Randomised, Controlled, Open-label Clinical Study to Evaluate the Efficacy and Safety of YL201 in Combination With Serplulimab Versus Carboplatin and Etoposide in Combination With Serplulimab as First-line Treatment in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer. Planned enrolment is 442 participants (estimated). The study started in 2026-08-18 and primary completion is expected in 2029-06. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT07739758
- Phase: 3
- Setting: A Phase III, Multicenter, Randomized, Controlled, Open-label Clinical Study to Evaluate the Efficacy and Safety of YL201 in Combination With Serplulimab Versus Carboplatin and Etoposide in Combination With Serplulimab as First-line Treatment in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer
- Sponsor: MediLink Therapeutics (Suzhou)
- Enrolled: 442

## Sources

- ClinicalTrials.gov NCT07739758: https://clinicaltrials.gov/study/NCT07739758

## Connected records

- cancers: [Extensive-stage small-cell lung cancer](https://onco.cc/cancers/extensive-stage-sclc/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [YL201](https://onco.cc/drugs/yl201/)
- companies: [MediLink Therapeutics](https://onco.cc/companies/medilink/)

---
JSON: https://onco.cc/api/v1/entities/nct07739758.json